Estrogen Hydroxylation in Osteoporosis

Nicola Napoli, Reina Armamento-Villareal

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Estrogen is metabolized predominantly via two competing pathways, the 2-hydroxyl (nonestrogenic) and the 16α-hydroxyl (estrogenic) pathways. Studies have indicated that these pathways are important determinants of bone mineral density (BMD) in postmenopausal women. Women with predominant metabolism through the 2-hydroxyl pathway have accelerated postmenopausal bone loss and lower BMD compared to those with predominant 16α-hydroxylation who are protected from bone loss. Increased 2-hydroxylation has been observed in women with a positive family history of osteoporosis suggesting that the increased risk of osteoporosis in those with family history may, in part, be related to inherited differences in estrogen metabolism. Polymorphisms in the cytochrome P450 (CYP450) enzymes that metabolize estrogen are believed to result in alteration in the activity of these enzymes leading to differences in estrogen hydroxylation. It is the resulting "estrogen tone" generated from the variable accumulation of metabolic products with divergent estrogenic activity that has been hypothesized to modify the risks for hormone-dependent disorders associated with these polymorphisms, for example, osteoporosis. In support of this notion is the finding of lower BMD in women with the A allele for the C4887A polymorphism of the CYP1A1 gene, who are found to have accelerated rate of estrogen hydroxylation. These findings may have broader clinical significance as recent data indicate that women with predominance of the 2-hydroxyl pathway appear to have better BMD response to estrogen/hormone replacement therapy (ERT/HRT) compared to those with predominant 16α-hydroxylation. It is likely that individual responses to ERT/HRT may vary according to patterns of estrogen hydroxylation, in turn a result of varying activity of the different CYP450 enzyme variants, thus, allowing the future possibility of identifying responders by genetic and/or metabolic profiling.

Original languageEnglish
Pages (from-to)211-227
Number of pages17
JournalAdvances in Clinical Chemistry
Volume43
DOIs
Publication statusPublished - 2007

Fingerprint

Hydroxylation
Osteoporosis
Estrogens
Bone
Hydroxyl Radical
Bone Density
Cytochrome P-450 Enzyme System
Minerals
Polymorphism
Metabolism
Hormones
Postmenopausal Osteoporosis
Cytochrome P-450 CYP1A1
Estrogen Replacement Therapy
Hormone Replacement Therapy
Alleles
Genes
Bone and Bones
Enzymes

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Estrogen Hydroxylation in Osteoporosis. / Napoli, Nicola; Armamento-Villareal, Reina.

In: Advances in Clinical Chemistry, Vol. 43, 2007, p. 211-227.

Research output: Contribution to journalArticle

Napoli, Nicola ; Armamento-Villareal, Reina. / Estrogen Hydroxylation in Osteoporosis. In: Advances in Clinical Chemistry. 2007 ; Vol. 43. pp. 211-227.
@article{c908141a640c4d88b447dc2e65e82ed0,
title = "Estrogen Hydroxylation in Osteoporosis",
abstract = "Estrogen is metabolized predominantly via two competing pathways, the 2-hydroxyl (nonestrogenic) and the 16α-hydroxyl (estrogenic) pathways. Studies have indicated that these pathways are important determinants of bone mineral density (BMD) in postmenopausal women. Women with predominant metabolism through the 2-hydroxyl pathway have accelerated postmenopausal bone loss and lower BMD compared to those with predominant 16α-hydroxylation who are protected from bone loss. Increased 2-hydroxylation has been observed in women with a positive family history of osteoporosis suggesting that the increased risk of osteoporosis in those with family history may, in part, be related to inherited differences in estrogen metabolism. Polymorphisms in the cytochrome P450 (CYP450) enzymes that metabolize estrogen are believed to result in alteration in the activity of these enzymes leading to differences in estrogen hydroxylation. It is the resulting {"}estrogen tone{"} generated from the variable accumulation of metabolic products with divergent estrogenic activity that has been hypothesized to modify the risks for hormone-dependent disorders associated with these polymorphisms, for example, osteoporosis. In support of this notion is the finding of lower BMD in women with the A allele for the C4887A polymorphism of the CYP1A1 gene, who are found to have accelerated rate of estrogen hydroxylation. These findings may have broader clinical significance as recent data indicate that women with predominance of the 2-hydroxyl pathway appear to have better BMD response to estrogen/hormone replacement therapy (ERT/HRT) compared to those with predominant 16α-hydroxylation. It is likely that individual responses to ERT/HRT may vary according to patterns of estrogen hydroxylation, in turn a result of varying activity of the different CYP450 enzyme variants, thus, allowing the future possibility of identifying responders by genetic and/or metabolic profiling.",
author = "Nicola Napoli and Reina Armamento-Villareal",
year = "2007",
doi = "10.1016/S0065-2423(06)43007-9",
language = "English",
volume = "43",
pages = "211--227",
journal = "Advances in Clinical Chemistry",
issn = "0065-2423",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Estrogen Hydroxylation in Osteoporosis

AU - Napoli, Nicola

AU - Armamento-Villareal, Reina

PY - 2007

Y1 - 2007

N2 - Estrogen is metabolized predominantly via two competing pathways, the 2-hydroxyl (nonestrogenic) and the 16α-hydroxyl (estrogenic) pathways. Studies have indicated that these pathways are important determinants of bone mineral density (BMD) in postmenopausal women. Women with predominant metabolism through the 2-hydroxyl pathway have accelerated postmenopausal bone loss and lower BMD compared to those with predominant 16α-hydroxylation who are protected from bone loss. Increased 2-hydroxylation has been observed in women with a positive family history of osteoporosis suggesting that the increased risk of osteoporosis in those with family history may, in part, be related to inherited differences in estrogen metabolism. Polymorphisms in the cytochrome P450 (CYP450) enzymes that metabolize estrogen are believed to result in alteration in the activity of these enzymes leading to differences in estrogen hydroxylation. It is the resulting "estrogen tone" generated from the variable accumulation of metabolic products with divergent estrogenic activity that has been hypothesized to modify the risks for hormone-dependent disorders associated with these polymorphisms, for example, osteoporosis. In support of this notion is the finding of lower BMD in women with the A allele for the C4887A polymorphism of the CYP1A1 gene, who are found to have accelerated rate of estrogen hydroxylation. These findings may have broader clinical significance as recent data indicate that women with predominance of the 2-hydroxyl pathway appear to have better BMD response to estrogen/hormone replacement therapy (ERT/HRT) compared to those with predominant 16α-hydroxylation. It is likely that individual responses to ERT/HRT may vary according to patterns of estrogen hydroxylation, in turn a result of varying activity of the different CYP450 enzyme variants, thus, allowing the future possibility of identifying responders by genetic and/or metabolic profiling.

AB - Estrogen is metabolized predominantly via two competing pathways, the 2-hydroxyl (nonestrogenic) and the 16α-hydroxyl (estrogenic) pathways. Studies have indicated that these pathways are important determinants of bone mineral density (BMD) in postmenopausal women. Women with predominant metabolism through the 2-hydroxyl pathway have accelerated postmenopausal bone loss and lower BMD compared to those with predominant 16α-hydroxylation who are protected from bone loss. Increased 2-hydroxylation has been observed in women with a positive family history of osteoporosis suggesting that the increased risk of osteoporosis in those with family history may, in part, be related to inherited differences in estrogen metabolism. Polymorphisms in the cytochrome P450 (CYP450) enzymes that metabolize estrogen are believed to result in alteration in the activity of these enzymes leading to differences in estrogen hydroxylation. It is the resulting "estrogen tone" generated from the variable accumulation of metabolic products with divergent estrogenic activity that has been hypothesized to modify the risks for hormone-dependent disorders associated with these polymorphisms, for example, osteoporosis. In support of this notion is the finding of lower BMD in women with the A allele for the C4887A polymorphism of the CYP1A1 gene, who are found to have accelerated rate of estrogen hydroxylation. These findings may have broader clinical significance as recent data indicate that women with predominance of the 2-hydroxyl pathway appear to have better BMD response to estrogen/hormone replacement therapy (ERT/HRT) compared to those with predominant 16α-hydroxylation. It is likely that individual responses to ERT/HRT may vary according to patterns of estrogen hydroxylation, in turn a result of varying activity of the different CYP450 enzyme variants, thus, allowing the future possibility of identifying responders by genetic and/or metabolic profiling.

UR - http://www.scopus.com/inward/record.url?scp=33845623833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845623833&partnerID=8YFLogxK

U2 - 10.1016/S0065-2423(06)43007-9

DO - 10.1016/S0065-2423(06)43007-9

M3 - Article

C2 - 17249385

AN - SCOPUS:33845623833

VL - 43

SP - 211

EP - 227

JO - Advances in Clinical Chemistry

JF - Advances in Clinical Chemistry

SN - 0065-2423

ER -